Mind Medicine (MindMed) Inc.
MMDCF
Other OTC0.01
USD
+0.00
- -
Mind Medicine (MindMed) Inc.
MMDCF
(Other OTC)
Recent
price
0.01
P/E
ratio
- -
div
yld
- -
ROIC.AI
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- Similar Companies
- Business
- Mind Medicine (MindMed) Inc. is a late-stage clinical biopharmaceutical company developing novel product candidates targeting brain health disorders. The company’s core products include proprietary pharmaceutical formulations such as MM-120 (LSD D-tartrate) designed for generalized anxiety disorder (GAD) and clinical depressive disorder; MM-402, a formulation of the R-enantiomer of MDMA, targeting autism spectrum disorder (ASD); and 18-MC, a non-hallucinogenic ibogaine derivative aimed at opioid withdrawal and opioid use disorder. MindMed focuses on serotonin receptor agonists and other neurotransmitter pathways relevant to brain health. The company operates primarily in North America, with ongoing clinical trials and regulatory activities aimed at the U.S. market. Founded in 2019, MindMed is headquartered in New York. In recent developments, MindMed completed a significant $259 million public equity offering in late 2025, including the full exercise of underwriters’ options, to fund research and development, clinical trials, working capital, and potential acquisitions. The proceeds are expected to support ongoing Phase 3 clinical trials for MM-120, with accelerated enrollment and topline data readouts projected for 2026, as well as the planned Phase 2a study initiation of MM-402 for ASD in late 2025. MindMed is advancing toward FDA submissions for both GAD and major depressive disorder (MDD) indications and maintains a strategic focus on expanding its pipeline through development and opportunistic acquisitions. The company reported cash and investments exceeding $200 million as of Q3 2025 to fund operations into 2028. MindMed positions itself as a key innovator within the psychedelic-inspired medicine field, addressing unmet needs in mental health and addiction treatment through both hallucinogenic and non-hallucinogenic therapeutics. Its pipeline combines drug development with a focus on rigorous clinical evidence, targeting markets of neuropsychiatric disorders such as anxiety, depression, autism spectrum disorder, and addiction. The company retains a vision to transform brain health treatments through novel mechanisms of action and has maintained sustained investor interest as it moves closer to potential commercial product launches.